Roth Capital Has Positive Estimate for TENX FY2024 Earnings

Tenax Therapeutics, Inc. (NASDAQ:TENX) – Stock analysts at Roth Capital increased their FY2024 EPS estimates for Tenax Therapeutics in a research note issued to investors on Wednesday, November 13th. Roth Capital analyst J. Aschoff now forecasts that the specialty pharmaceutical company will post earnings of ($1.16) per share for the year, up from their prior forecast of ($6.01). The consensus estimate for Tenax Therapeutics’ current full-year earnings is ($3.04) per share. Roth Capital also issued estimates for Tenax Therapeutics’ Q4 2024 earnings at ($0.17) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.86) EPS, FY2027 earnings at $1.82 EPS and FY2028 earnings at $3.08 EPS.

TENX has been the subject of several other reports. StockNews.com assumed coverage on Tenax Therapeutics in a research report on Thursday, September 26th. They issued a “sell” rating for the company. William Blair began coverage on Tenax Therapeutics in a report on Monday, September 30th. They set an “outperform” rating for the company. Guggenheim initiated coverage on shares of Tenax Therapeutics in a report on Monday, October 14th. They issued a “buy” rating and a $16.00 price objective on the stock. Leerink Partners started coverage on shares of Tenax Therapeutics in a research note on Thursday, October 24th. They set an “outperform” rating and a $16.00 target price for the company. Finally, Leerink Partnrs raised shares of Tenax Therapeutics to a “strong-buy” rating in a research note on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Tenax Therapeutics currently has a consensus rating of “Moderate Buy” and an average target price of $16.00.

Tenax Therapeutics Stock Performance

Shares of NASDAQ TENX opened at $4.87 on Monday. The company has a 50 day simple moving average of $3.99 and a 200-day simple moving average of $3.69. Tenax Therapeutics has a 1 year low of $2.77 and a 1 year high of $41.92.

Institutional Investors Weigh In On Tenax Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the company. Sphera Funds Management LTD. purchased a new position in Tenax Therapeutics during the 3rd quarter valued at about $101,000. Stonepine Capital Management LLC purchased a new stake in Tenax Therapeutics during the third quarter worth about $173,000. Finally, Vestal Point Capital LP acquired a new stake in shares of Tenax Therapeutics during the third quarter worth about $288,000. Hedge funds and other institutional investors own 1.67% of the company’s stock.

Tenax Therapeutics Company Profile

Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.